🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07525726
Recruiting Observational

The Relationship Between Finger Ratio and Development in Infants

NCT07525726 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-04-06
Last updated
2026-05-08

Condition(s) studied

Infant Developmental Assessment

Investigational drug(s) / intervention(s)

Digit RatioMotor developmentSensory processing functions

Digit Ratio: The lengths of the second (2D) and fourth (4D) fingers will be measured separately on each hand. Measurements will be taken with the baby's hands placed flat on a surface with palms facing upwards. Finger length will be defined as the distance from the midpoint of the proximal crease at the base of the finger to the distal end of the finger. A digital caliper with a precision of 0.01 mm will be used, and two separate measurements will be taken for each finger, with the average value recorded. Based on these measurements, the 2D:4D finger ratio for each hand will be calculated by dividing the length of the second finger by the length of the fourth finger.

Motor development: The Peabody Developmental Motor Scale-2 (PDMS-2) is planned to be used to assess motor development. The PDMS-2 test is designed to identify developmental delays in children aged 0-72 months. It is used to evaluate children's motor development with separate tests and rating scales for both gross and fine motor skills.

Sensory processing functions: The Test of Sensory Functions in Infants was planned for use to assess babies' sensory development. The TSFI is frequently used to evaluate the sensory processing functions of infants aged 4-18 months. It is used to determine whether and to what extent a baby has a sensory processing problem. It consists of 24 items. The TSFI requires the baby to be stimulated and interact with various materials. The total score ranges from 0-49, and the test has normative values for different age groups. Although it can be used from the fourth month onwards, the most reliable and valid results are obtained between 7-18 months.

Study summary

One of the most prominent indicators of prenatal androgen exposure is considered to be the ratio of second and fourth finger lengths (2D:4D). The 2D:4D finger ratio refers to the ratio of the length of the second finger (2D; index finger) and the fourth finger (4D; ring finger). Evidence suggests that 2D:4D is developmentally stable and stabilizes from the second trimester of pregnancy. It has been reported that the 2D:4D ratio correlates positively with estrogen and negatively with testosterone. In both sexes, prenatal testosterone levels are inversely related by a 2D:4D ratio, which does not change with age. Androgens can have direct trophic effects on target cells or indirectly affect neuronal growth through neurotrophic mediators released locally by steroid-sensitive neuronal or glial cells. Prenatal testosterone can have long-term organizational effects on the structure and function of various body systems (e.g., cardiovascular and musculoskeletal systems) that are important for physical activity and exercise.

Eligibility

Sex
ALL
Min age
12 Months
Max age
18 Months
Healthy volunteers
Accepted
Inclusion Criteria: * Term infants (37-40 weeks), * Infants aged 12-18 months Exclusion Criteria: * Preterm infants, * Infants with congenital infections or proven genetic changes, * Infants and mothers diagnosed with metabolic, neurological, and genetic diseases, * Maternal diabetes, * Intrauterine growth retardation, * Infants with a history of hand-related surgery, * Children whose parents did not volunteer to study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nigde Omer Halisdemir University Niğde Turkey (Türkiye) Recruiting

More Nigde Omer Halisdemir University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07525726 on ClinicalTrials.gov ↗ ← All trials in Turkey